Etilefrine

Identification

Summary

Etilefrine is an adrenergic agonist primarily of α1 and β1 receptors used as an anti-hypotensive.

Generic Name
Etilefrine
DrugBank Accession Number
DB08985
Background

Etilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors. It has been used as a vasoconstrictor agent.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
Thumb
Weight
Average: 181.2316
Monoisotopic: 181.110278729
Chemical Formula
C10H15NO2
Synonyms
  • Etilefrina
  • Etilefrine
  • Etilefrinum
External IDs
  • S 40032
  • S 40032-7

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbaloparatideThe risk or severity of adverse effects can be increased when Etilefrine is combined with Abaloparatide.
AcebutololThe therapeutic efficacy of Etilefrine can be decreased when used in combination with Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Etilefrine.
AcemetacinThe risk or severity of hypertension can be increased when Etilefrine is combined with Acemetacin.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Etilefrine.
AclidiniumThe risk or severity of Tachycardia can be increased when Aclidinium is combined with Etilefrine.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Etilefrine.
AlclofenacThe risk or severity of hypertension can be increased when Etilefrine is combined with Alclofenac.
AlfentanilThe risk or severity of hypertension can be increased when Alfentanil is combined with Etilefrine.
AlfuzosinThe therapeutic efficacy of Etilefrine can be decreased when used in combination with Alfuzosin.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Etilefrine hydrochlorideZBI6Q5FH3S943-17-9KTNROWWHOBZQGK-UHFFFAOYSA-N
International/Other Brands
Apocretin / Circupon / Effontil / Effortil / Effortilvet / Eti-Puren / Kertasin / Phetanol / Phetasin / Tonus-Forte / Updormin

Categories

ATC Codes
C01CA51 — Etilefrine, combinationsC01CA01 — Etilefrine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 1-hydroxy-4-unsubstituted benzenoids. These are phenols that are unsubstituted at the 4-position.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenols
Sub Class
1-hydroxy-4-unsubstituted benzenoids
Direct Parent
1-hydroxy-4-unsubstituted benzenoids
Alternative Parents
Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
1,2-aminoalcohol / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Alcohol / Amine / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Hydrocarbon derivative / Monocyclic benzene moiety
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
ZB6F8MY53V
CAS number
709-55-7
InChI Key
SQVIAVUSQAWMKL-UHFFFAOYSA-N
InChI
InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3
IUPAC Name
3-[2-(ethylamino)-1-hydroxyethyl]phenol
SMILES
CCNCC(O)C1=CC=CC(O)=C1

References

Synthesis Reference

British Patent 1,358,973.

General References
Not Available
KEGG Drug
D07931
PubChem Compound
3306
PubChem Substance
310264946
ChemSpider
3190
BindingDB
97154
RxNav
4169
ChEBI
91518
ChEMBL
CHEMBL86882
Wikipedia
Etilefrine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHepatic Ascites1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOral5 mg/mL
Capsule, extended release25 MG
Injection, solutionIntramuscular; Subcutaneous10 MG/1ML
Injection, solutionIntramuscular; Subcutaneous15 mg/ml
SolutionOral7.5 mg/mL
Solution / dropsOral7.5 MG/ML
TabletOral
TabletOral5 mg/1
Injection, solutionIntramuscular; Intravenous; Subcutaneous
Solution / dropsOral
SolutionOral7.5 mg
SolutionIntramuscular; Intravenous; Subcutaneous10 mg
Tablet, coatedOral5 mg
TabletOral5 mg
Tablet, sugar coatedOral5 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)208-209British Patent 1,358,973.
Predicted Properties
PropertyValueSource
Water Solubility13.8 mg/mLALOGPS
logP0.01ALOGPS
logP0.23ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)9.1ChemAxon
pKa (Strongest Basic)9.73ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area52.49 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity52 m3·mol-1ChemAxon
Polarizability20.33 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-05no-3900000000-dc75520c0fb8e17d3ef6

Drug created on June 10, 2014 17:55 / Updated on June 02, 2021 20:03